217 related articles for article (PubMed ID: 23598960)
21. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
[TBL] [Abstract][Full Text] [Related]
22. CORR Insights®: Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Ramsey DC
Clin Orthop Relat Res; 2024 Jun; 482(6):957-959. PubMed ID: 38446419
[No Abstract] [Full Text] [Related]
23. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
Joseph NM; McGill KC; Horvai AE
Am J Surg Pathol; 2021 Jun; 45(6):812-819. PubMed ID: 33239505
[TBL] [Abstract][Full Text] [Related]
24. Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature.
Gambarotti M; Pacheco M; Ruengwanichayakun P; Silvino Vega Jiménez B; Benini S; Bianchi G; Sbaraglia M; Vanel D; Carretta E; Bertoni F; Franchi A; Dei Tos AP; Righi A
Histopathology; 2020 Sep; 77(3):391-401. PubMed ID: 32506447
[TBL] [Abstract][Full Text] [Related]
25. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
26. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
27. Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.
Hao S; Hong CS; Feng J; Yang C; Chittiboina P; Zhang J; Zhuang Z
J Neurosurg; 2016 Jun; 124(6):1562-7. PubMed ID: 26473790
[TBL] [Abstract][Full Text] [Related]
28. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.
Salas S; de Pinieux G; Gomez-Brouchet A; Larrousserie F; Leroy X; Aubert S; Decouvelaere AV; Giorgi R; Fernandez C; Bouvier C
Virchows Arch; 2009 Jan; 454(1):81-7. PubMed ID: 19050913
[TBL] [Abstract][Full Text] [Related]
29. Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.
Gomez-Brouchet A; Mourcin F; Gourraud PA; Bouvier C; De Pinieux G; Le Guelec S; Brousset P; Delisle MB; Schiff C
Hum Pathol; 2010 Sep; 41(9):1220-30. PubMed ID: 20399482
[TBL] [Abstract][Full Text] [Related]
30. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
31. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
Makise N; Sekimizu M; Konishi E; Motoi T; Kubo T; Ikoma H; Watanabe SI; Okuma T; Hiraoka N; Fukayama M; Kawai A; Ichikawa H; Yoshida A
Mod Pathol; 2019 Mar; 32(3):435-445. PubMed ID: 30291346
[TBL] [Abstract][Full Text] [Related]
32. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
33. Induction of sarcomas by mutant IDH2.
Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
[TBL] [Abstract][Full Text] [Related]
34. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.
Meijer D; de Jong D; Pansuriya TC; van den Akker BE; Picci P; Szuhai K; Bovée JV
Genes Chromosomes Cancer; 2012 Oct; 51(10):899-909. PubMed ID: 22674453
[TBL] [Abstract][Full Text] [Related]
35. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
[TBL] [Abstract][Full Text] [Related]
36. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
Jiang L; Liu J; Wei Q; Wang Y
Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
38. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
[No Abstract] [Full Text] [Related]
39. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma.
Grote HJ; Schneider-Stock R; Neumann W; Roessner A
Virchows Arch; 2000 May; 436(5):494-7. PubMed ID: 10881744
[TBL] [Abstract][Full Text] [Related]
40. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]